|
|
|
 |
November 21, 2006 PRESS RELEASE Clifton Mining Company Inc. (OTC : CFTN) US PATENT OFFICE ISSUES LANDMARK The United States Patent and Trademark Office has just issued a landmark silver product and use patent to American Silver, LLC parent company of American Biotech Labs, LLC (ABL). ABL is a private company of which Clifton owns 23%. The patent number is 7,135,195 and the patent can be accessed from search engines or directly from this page. THE NEW PATENT Previous patents issued to ABL had governed the unique technology used in the production of its nano-particle silver. The new patent governs both the product itself, covering a wide range of particle sizes, and as an agent against organisms harmful to the health of humans. Said Keith Moeller, a managing director of ABL, “We believe this new patent sets us apart from all other silver products. This patent is proof that our nano-silver technology is unique as well as effective. It will provide additional protection for our planned release of new products anticipated in the first quarter of 2007, including an animal wound care product and a cosmetic that helps promote natural healing. ABL products are already available in quality neighborhood health food and national chain stores like GNC.” WHERE TO FIND IT The new patent can be accessed through the US Patent and Trademark Office under the new patent number 7,135,195. For direct internet access go to http://patft.uspto.gov/netahtml/PTO/srchnum.htm and enter in the patent number 7,135,195. This patent is the third issued to ABL. ABL has additional patents pending. Clifton trades on the U.S. OTC: (CFTN). For additional information, contact Dr. Ken Friedman, President at 303-642-0659, Keith Moeller, Vice President at 801-756-1414 or see our website at www.cliftonmining.com or American Biotech Labs at www.americanbiotechlabs.com. Note: Any statements released by Clifton Mining Company that are forward looking are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Editors and investors are cautioned that forward looking statements invoke risk and uncertainties that may affect the company’s business prospects and performance. |
